文献速递淋巴瘤

自适应制备的慢病毒抗CD20/抗CD19嵌合抗原受体T细胞治疗复发难治性套细胞淋巴瘤的I/II期研究

Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma.
PubMed 文献 · J Clin Oncol · 2025-03-31

这项I/II期临床试验评估了在复发难治性套细胞淋巴瘤患者中,使用自适应8至12天制备工艺在-site生产的慢病毒抗CD20/抗CD19 CAR T细胞。17例患者接受2.5×10^6细胞/kg单次输注,最佳总缓解率为100%(完全缓解88%,部分缓解12%),中位随访15.8个月时中位无进展生存期和总生存期均未达到。细胞因子释放综合征发生率为94%(均为1-2级),18%发生免疫效应细胞相关神经毒性综合征。

要点

  • 17例复发难治性套细胞淋巴瘤患者接受2.5×10^6细胞/kg的LV20.19 CAR T细胞单次输注。
  • 最佳总缓解率为100%,其中完全缓解88%,部分缓解12%,II期第90天完全缓解率疗效阈值被超越。
  • 94%发生细胞因子释放综合征(均为1-2级),18%发生免疫效应细胞相关神经毒性综合征,3例非复发死亡均发生于持续B细胞发育不全背景下。

核心结论

  • 在-site自适应制备的LV20.19 CAR T细胞对复发难治性套细胞淋巴瘤可行、安全且有效,最佳总缓解率为100%,安全性特征良好,迄今复发例数少。

研究设计与样本

  • I/II期临床试验(ClinicalTrials.gov标识符:NCT04186520),纳入至少两线治疗失败或移植后复发的套细胞淋巴瘤患者。
  • LV20.19 CAR T细胞通过CliniMACS Prodigy在-site采用自适应8至12天工艺制备,以优化最终CAR产品中naïve和干细胞记忆样(SCM)T细胞数量。
  • 17例复发难治性套细胞淋巴瘤患者接受单次剂量2.5×10^6细胞/kg的LV20.19 CAR T细胞输注(I期3例,II期14例)。

主要发现

  • 最佳总缓解率为100%(完全缓解88%,部分缓解12%),II期第90天完全缓解率疗效阈值被超越。
  • 截至数据截止时2例患者复发,中位随访15.8个月时中位无进展生存期和总生存期均未达到。
  • 94%(n=16)发生细胞因子释放综合征,均为1-2级;18%(n=3)在最初28天内发生免疫效应细胞相关神经毒性综合征,其中2例为可逆性3级毒性。
  • 3例患者发生非复发死亡事件,均发生于持续B细胞发育不全背景下。
  • 最终LV20.19 CAR产品富集了更高比例的T-SCM/T-naïve细胞,大多数患者在白细胞分离术后8天内接受CAR T细胞输注。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy characterized by t(11;14) and bright CD20 expression. To improve outcomes from single targeted CD19 chimeric antigen receptor (CAR) T cells, we used dual targeted lentiviral anti-CD20/anti-CD19 (LV20.19) CAR T cells as part of a phase I/II clinical trial in relapsed, refractory (R/R) MCL (ClinicalTrials.gov identifier: NCT04186520). METHODS: Patients with MCL who had failed two lines of therapy or relapsed post-transplant were eligible. LV20.19 CAR T cells were manufactured on-site via CliniMACS Prodigy using an adaptive 8- to 12-day process to optimize the final CAR product for increased numbers of naïve and stem-cell memory (SCM) like T cells. RESULTS: Seventeen patients with R/R MCL received a single dose of LV20.19 CAR T cells at 2.5 × 106 cells/kg (phase I = three patients; phase II = 14 patients). The best overall response rate (ORR) was 100% (complete response [CR] = 88%; partial response = 12%) and the phase II efficacy threshold for day-90 CR rate was exceeded. Two patients have relapsed as of the data cutoff and neither the median progression-free survival nor overall survival has been reached with a median follow-up of 15.8 months. Ninety-four percent (n = 16) experienced cytokine release syndrome, all grade 1-2. Eighteen percent (n = 3) had immune effector cell-associated neurotoxicity syndrome in the first 28-days, two with reversible grade 3 toxicity. Three patients had nonrelapse mortality events; all occurred in the setting of ongoing B-cell aplasia. The final LV20.19 CAR products were enriched for higher percentages of T-SCM/T-naïve cells and most patients received CAR T cells within 8 days of apheresis. CONCLUSION: In conclusion, we demonstrate that on-site adaptive manufactured LV20.19 CAR T cells are feasible, safe, and efficacious for R/R MCL with best ORR of 100%, a favorable safety profile, and few relapses to date.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Shah NN, Colina AS, Johnson BD, et al. Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma. J Clin Oncol. 2025. PMID: 40163793. doi:10.1200/JCO-24-02158

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。